|
Condensed Consolidated Statement of Operations (USD $)
In Thousands, except Per Share data, unless otherwise specified
|
3 Months Ended |
|
Mar. 31, 2014
|
Mar. 31, 2013
|
| Revenue: |
|
|
| License and research revenue |
$ 1,433 |
$ 1,273 |
| Product sales and services |
5,940 |
2,107 |
| Other revenues |
1,802 |
1,760 |
| Total revenue |
9,175 |
5,140 |
| Costs and expenses: |
|
|
| Cost of goods and services sold |
(1,952) |
(995) |
| Research and development |
(7,094) |
(8,529) |
| Selling, general and administrative |
(3,555) |
(2,491) |
| Fair value remeasurement of acquisition liabilities, incl. related parties |
(14,626) |
(2,976) |
| Acquisition note expenses, incl. related parties |
(3,013) |
0 |
| Amortisation of intangible R&D assets |
(2,937) |
0 |
| Total |
(33,177) |
(14,991) |
| Profit (loss) from operations |
(24,002) |
(9,851) |
| Interest income net |
(5,508) |
(429) |
| Interest expense on debt related to the royalty agreement with related parties |
(156) |
0 |
| Foreign exchange gain (loss) |
179 |
24 |
| Other income (loss) |
52 |
(35) |
| Income (loss) before income taxes |
(29,435) |
(10,291) |
| Income tax benefit (expense) |
2,797 |
1,462 |
| Net income (loss) |
$ (26,638) |
$ (8,829) |
| Earnings (loss) per share |
|
|
| Basic earnings (loss) per ordinary share |
$ (0.94) |
$ (0.35) |
| Diluted earnings (loss) per share |
$ (0.94) |
$ (0.35) |
| Weighted average number of shares outstanding (in thousands) : |
|
|
| Basic (in shares) |
28,312 |
25,415 |
| Diluted (in shares) |
28,312 |
25,415 |